FILSUVEZ®, developed by Chiesi Global Rare Diseases, is a prescription topical gel that supports wound healing in Dystrophic and Junctional Epidermolysis Bullosa. It is the first U.S. FDA approved treatment for Junctional EB and the second for Dystrophic EB.
FILSUVEZ®
Overview
|
EB Type |
Dystrophic Epidermolysis Bullosa (DEB), Junctional Epidermolysis Bullosa (JEB) |
|---|---|
|
Approved Age |
6 months of age or older |
|
Dosage and Administration |
Topical gel: 10% birch triterpenes w/w supplied in 25 mL sterile tubes. For use on the skin (topical use) only. Do not use FILSUVEZ in or around your eyes or mucous membranes (for example, the mouth, vagina, or anus). Use FILSUVEZ exactly as your healthcare provider tells you to use it. Clean wounds before applying FILSUVEZ as instructed by your healthcare provider. Apply a 1 mm layer of FILSUVEZ to the affected wound surface and cover with wound dressing or apply FILSUVEZ directly to dressing so that the topical gel is in direct contact with the wound. Do not rub in the topical gel. Each tube of FILSUVEZ is for one-time use only. |
|
Preparation |
Wash your hands with soap and water or wear gloves. Open a new tube of FILSUVEZ. Apply the gel right away. |
|
How Often |
Apply FILSUVEZ at wound dressing changes until the wound is healed. |
|
Adverse Reactions |
The most common side effect of FILSUVEZ is application site reactions, such as pain and itchy skin. Call your doctor for medical advice about side effects. |
|
Prescribing Information |
Full Prescribing Information |
Getting Started
Chiesi Total Care Support Program will guide you or your loved one with EB through the process of getting started on FILSUVEZ® (birch triterpenes) topical gel. Their dedicated team is made up of pharmacists, patient service coordinators, reimbursement supports specialists, and nursing support, and can help with items such as insurance coverage.